SCNI

Scinai Immunotherapeutics Ltd. (SCNI) Business Model Analysis (2026)

Invetso Score: 4.6/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Value Proposition Revenue Model

Score: 4.8 (Moderate)

R&D-heavy revenue model: R&D at 132.1% of revenue indicates a development-led model, which can support differentiated products but currently suppresses near-term margin conversion.

Low asset productivity: Asset turnover of 0.09x implies capital is not yet generating meaningful revenue, limiting operating efficiency versus more mature peers.

Capex-light commercialization: Capex at 8.6% of revenue suggests limited physical reinvestment needs, which can aid scalability if product demand converts efficiently.

Cost Structure

Score:

High fixed development burden: R&D intensity dominates the cost base, creating structural pressure on margins until revenue scales enough to absorb development spend.

Moderate equity compensation load: Stock-based compensation at 2.3% of revenue adds recurring non-cash dilution pressure, though it is not the primary cost driver.

Low capex burden: Capex intensity is modest, which reduces maintenance spending needs relative to asset-heavy peers and supports eventual operating leverage.

Scalability Operating Leverage

Score:

Operating leverage is not yet visible: The combination of very low asset turnover and heavy R&D spend indicates the model has not yet translated into efficient scale economics.

Potential software-like scaling profile: Low capex intensity can support faster scaling than industrial peers if revenue growth outpaces fixed development costs.

Peer-relative constraint: Compared with established peers that monetize existing assets more efficiently, SCNI appears earlier in the scaling curve and less leveraged.

Customer Structure Concentration

Score:

Customer concentration not disclosed in provided metrics: The available data do not show customer concentration, limiting confidence in revenue diversification and contract visibility.

Model likely depends on conversion quality: With weak asset productivity, revenue durability likely depends on whether a limited set of offerings can achieve repeatable adoption.

Revenue Quality Predictability

Score:

Income quality is weak: Income quality of 2.8x suggests earnings and cash generation are not tightly aligned, reducing predictability versus higher-quality peers.

Cash conversion remains unclear: FCF margin is unavailable, but the combination of high R&D and weak income quality points to limited near-term cash visibility.

Revenue quality depends on commercialization: The model appears more dependent on future product adoption than on recurring, contract-backed revenue streams.

Overall Score

Score:

SCNI has a development-led model with low capex needs, but heavy R&D intensity, weak asset productivity, and poor income quality limit scalability and predictability.

Score Driver: The Dominant Driver Is An R&D-Intensive Structure That Can Support Future Differentiation, But Current Revenue Efficiency And Cash Conversion Remain Structurally Weak.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Scinai Immunotherapeutics Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →